drugset / Trial / NCT07229716

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

NCT07229716 ↗

Phase 1 Completed 20 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.

Timeline

Start
2026-04-04
Primary completion
2026-06-18
Completion
2026-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9813 Unknown — Oral
Subject Nintedanib Small molecule — —
Subject Pirfenidone Small molecule — —

Indications